LIMN earnings date and last-quarter result: P/E -0.30. Updated 2026-07-23.
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Research Hub
Liminatus Pharma, Inc. Class A Common Stock (LIMN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.16 USD (+7.48%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.30, market cap 0.00B. This hub links to the full technical, earnings and options research available for LIMN.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.16 USD (+7.48%) |
| 52-week range | 2.91 USD – 10.35 USD |
| Trend regime | Range |
| 14-day RSI | 35.3 (Bearish) |
| Trailing P/E | -0.30 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
Available research for LIMN
Covered Call on LIMN: how it works, illustrative setup around the real 3.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LIMN: how it works, illustrative setup around the real 3.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LIMN: how it works, illustrative setup around the real 3.16 USD price, max profit/loss, breakeven and when to use it. Educational.
LIMN technical analysis: range, last 3.16 USD, RSI 35.3, 52w range 2.91 USD–10.35 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is LIMN in?
Liminatus Pharma, Inc. Class A Common Stock (LIMN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LIMN in an uptrend or downtrend?
As of 2026-10-26, LIMN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LIMN's trailing P/E ratio?
LIMN's trailing P/E is -0.30, with a market cap of 0.00B. See the earnings research page for full valuation detail.